Montelukast dicyclohexylamine
Based on 15 publication(s) in Google Scholar
Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research.
For research use only. We do not sell to patients.
- CAS No.: 577953-88-9
- Formula: C47H59ClN2O3S
- Molecular Weight:767.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Montelukast dicyclohexylamine
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Adv Mater. 2024 Jun;36(24):e2311760. [Abstract]
- Nat Commun. 2025 Apr 3;16(1):3177. [Abstract]
- J Cachexia Sarcopenia Muscle. 2022 Aug;13(4):2242-2253. [Abstract]
- Cell Rep. 2026 Jun 2;45(6):117490. [Abstract]
- Cell Rep. 2025 Apr 16;44(5):115572. [Abstract]
- Anal Chem. 2025 Nov 18;97(45):25158-25167. [Abstract]
- Environ Pollut. 2026 May 1:396:127849. [Abstract]
- Eur J Pharmacol. 2022 May 15;923:174892. [Abstract]
- Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):4234-4239. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2023 Aug;396(8):1759-1771. [Abstract]
- SSRN. 2024 Oct 29.
- Patent. US20230404992A1.
- Patent. US20230348536A1.
- Patent. US20210309696A1.
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Flow Cytometry
All Leukotriene Receptor Isoforms
More
Biological Activity
Description
IC50 & Target
|
CysLT1 |
In Vitro
Montelukast (5 μM; 1 h) inhibits APAP (Acetaminophen) (HY-66005)-induced cell damage[1].
Montelukast (0.01-10 μM; 30 min) diminishes the 5-oxo-ETE–induced cell migration and modulates the activation of the plasmin-plasminogen system[3].
Montelukast (10 μM; 18 h) modulates the activation of MMP-9[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Eosinophils
-
Concentration:0.01-10 μM
-
Incubation Time:30 min
-
Result:Diminished the 5-oxo-ETE–induced cell migration.
-
Cell Line:Eosinophils
-
Concentration:10 μM
-
Incubation Time:18 h
-
Result:Reduced the 5-oxo-ETE–boosted MMP-9 secretion.
In Vivo
Montelukast (1 mg/kg; miniosmotic pump administration) reduces the airway remodeling changes observed in OVA-treated mice and blocks the actions of cysteinyl leukotrienes (LT) C4, D4, and E4 mediated by the CysLT1 receptor[2].
Montelukast (1 mg/kg; miniosmotic pump administration) reduces the elevated levels of IL-4 and IL-13 found in the BAL fluid of OVA-treated mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (8-week-old; 22-25 g) are induced acute hepatic injury[1]
-
Dosage:3 mg/kg
-
Administration:Oral gavage 1 h after saline or APAP administration
-
Result:Decreased serum levels of alanine transaminase (ALT) and aspartate aminotransferase (AST), and alleviated liver damage.
Chemical Information
-
CAS No. 577953-88-9
-
Appearance Solid
-
Molecular Weight 767.50
-
Formula C47H59ClN2O3S
-
Color White to off-white
-
SMILES
CC(C)(O)C(C=CC=C1)=C1CC[C@H](C2=CC(/C=C/C3=NC4=C(C=CC(Cl)=C4)C=C3)=CC=C2)SCC5(CC5)CC(O)=O.C6(CCCCC6)NC7CCCCC7
-
Synonyms
MK0476 dicyclohexylamine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (15)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Adv Mater
Efficient Delivery of Lomitapide using Hybrid Membrane-Coated Tetrahedral DNA Nanostructures for Glioblastoma Therapy. [Abstract]2024 Jun;36(24):e2311760. PMID: 38569065 -
Nat Commun
Cholangiocarcinoma PDHA1 succinylation suppresses macrophage antigen presentation via alpha-ketoglutaric acid accumulation. [Abstract]2025 Apr 3;16(1):3177. PMID: 40180922
Montelukast dicyclohexylamine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Apr 3;16(1):3177. [Abstract]
Schematic diagram of subcutaneous tumor treatment on C57BL/6 mice and representative images of Montelukast (5 mg/kg; i.p.; 7-26 d) on day 26.
Montelukast dicyclohexylamine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Apr 3;16(1):3177. [Abstract]
Tumor growth of LTP-C9 with overexpression of PDHA1 WT was observed in C57BL/6 mice treated with Montelukast (5 mg/kg; i.p.; 7-26 d).
-
J Cachexia Sarcopenia Muscle
A disease-associated missense mutation in CYP4F3 affects the metabolism of leukotriene B4 via disruption of electron transfer. [Abstract]2022 Aug;13(4):2242-2253. PMID: 35686338 -
Cell Rep
HSPA6 maintains IMPDH2 phosphorylation to regulate GTP synthesis for driving radioresistance of glioblastoma stem cells. [Abstract]2026 Jun 2;45(6):117490. PMID: 42234559 -
Cell Rep
2025 Apr 16;44(5):115572. PMID: 40249703 -
Anal Chem
A Computational Integration Strategy Driven by Chemical Similarity Uncovers Comprehensive Metabolic Profiles of Small Bioactive Peptides via UHPLC-HRMS for Doping Control. [Abstract]2025 Nov 18;97(45):25158-25167. PMID: 41202118 -
Environ Pollut
Enantioselective metabolic mechanism and metabolism pathway of tetraconazole in human liver microsomes: In vitro and in silico study. [Abstract]2026 May 1:396:127849. PMID: 41720237
Montelukast dicyclohexylamine purchased from MedChemExpress. Usage Cited in: Environ Pollut. 2026 May 1:396:127849. [Abstract]
Effect of Montelukast (Mon) (500 μM) on the metabolic inhibition rate of tetraconazole enantiomers in the in vitro incubation mixtures with HLMs.
-
Eur J Pharmacol
Montelukast, cysteinyl leukotriene receptor 1 antagonist, inhibits cardiac fibrosis by activating APJ. [Abstract]2022 May 15;923:174892. PMID: 35358494 -
Artif Cells Nanomed Biotechnol
Montelukast promotes mitochondrial biogenesis via CREB/PGC-1α in human bronchial epithelial cells. [Abstract]2019 Dec;47(1):4234-4239. PMID: 31722576 -
Naunyn Schmiedebergs Arch Pharmacol
Combined contributions of cytochrome P450s (CYPs) and non-enzymatic metabolism in the in vitro biotransformation of anaprazole, a novel proton pump inhibitor. [Abstract]2023 Aug;396(8):1759-1771. PMID: 36847804 -
Montelukast dicyclohexylamine purchased from MedChemExpress. Usage Cited in: SSRN. 2024 Oct 29.
Montelukast (M) (2.5-5.0 mg/kg; i.p.; once daily for 19 weeks) reduced urine protein levels and concentrations of autoantibodies, including ANA and anti-dsDNA of MRL/Lpr mice.
Montelukast dicyclohexylamine purchased from MedChemExpress. Usage Cited in: SSRN. 2024 Oct 29.
Montelukast (M) (2.5-5.0 mg/kg; i.p.; once daily for 19 weeks) decreased the percentages of ASCs, plasma cells, and plasmablasts in the spleen of MRL/Lpr mice.
-
-
-
Purity & Documentation
References
[1]. Pu S, et, al. Montelukast Prevents Mice Against Acetaminophen-Induced Liver Injury. Front Pharmacol. 2019 Sep 18; 10:1070. [Content Brief]
[2]. William RHJ, et, al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002 Jan 1; 165(1): 108-16. [Content Brief]
[3]. Langlois A, et al. Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism. J Allergy Clin Immunol. 2006;118(1):113-119. [Content Brief]
[4]. Khan AR, et al. Montelukast in hospitalized patients diagnosed with COVID-19. J Asthma. 2022 Apr;59(4):780-786. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Montelukast dicyclohexylamine Related Classifications
HY-13315B Related Classifications
Powered by Bioz